Abstract
Will CD40 and its ligand allow development of new immune-regulating drugs and human MAbs?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vetrie, D. et al. 1993. Nature 361: 226–233.
Tsukada, S. et al. 1993. Cell 72: 279–290.
Mayer, L. 1983. New Eng. J. Med. 314: 409–413.
Armitage, R. et al. 1992. Ear. J. Immunology 22: 2071–2076.
Armitage, R. et al. 1992. Nature 357: 80–82.
Spriggs, M. et al. 1992. J. Exp. Med. 176: 1543–1550.
Graf, D. et al. 1992. Ear. J. Immunology 22: 3191–3194.
Hollenbaugh, D. et al. 1992. EMBO 11: 4313–4321.
Allen, R. et al. 1993. Science 259: 990–993.
Maliszewski, C. et al. 1993. Eur. J. Immunology 23: 1044–1049.
Liu, Y.J. et al. 1989. Nature 342: 929–931.
Alderson, M. et al. 1993. J. Exp. Med. 178: 169–174.
Fanslow, W. et al. 1992. J. Immunology 149: 655–660.
Banchereau, J. and Rousset, F. 1991. Clin. Immunology Spectrum 3: 1–3.
Rights and permissions
About this article
Cite this article
Edgington, S. Biotherapies and B-Cell Differentiation. Nat Biotechnol 11, 998–1000 (1993). https://doi.org/10.1038/nbt0993-998
Issue Date:
DOI: https://doi.org/10.1038/nbt0993-998